Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover, bioequivalence study comparing Fenofibrate capsules,
USP 130 mg manufactured by Ohm Laboratories Inc, NJ 08901 with ANTARA® (fenofibrate) capsules
130 mg manufactured by Ethypharm Industries Saint Cloud, France for Oscient Pharmaceuticals
Corp. Waltham, MA 02451 in healthy, adult, male, human subjects under fed condition.